{"database":"iProX","file_versions":[],"scores":null,"additional":{"omics_type":["Proteomics"],"submitter":["Wenqing Jia"],"species":["Homo Sapiens"],"full_dataset_link":["http://www.iprox.org/page/project.html?id=IPX0009716000"],"submitter_email":["coffeemd@163.com"],"submitter_affiliation":["Beijing Tiantan Hospital, Capital Medical University"],"sample_protocol":[""],"repository":["iProX"],"data_protocol":[""],"pubmed_abstract":["<h4>Background</h4>Spinal ependymal tumors are a diverse group of neoplasms encompassing four subtypes: spinal ependymoma (SP-EPN), spinal ependymoma, MYCN-amplification (SP-EPN-MYCN), spinal myxopapillary ependymoma (SP-MPE), and spinal subependymoma (SP-SE). However, the molecular differences among these subtypes remain largely unknown.<h4>Methods</h4>Using an integrated multi-omics approach (whole-genome sequencing, RNA-seq, and mass spectrometry), we identified the distinct molecular characteristics of three subtypes except for SP-EPN-MYCN.<h4>Results</h4>In SP-EPN, abnormal enrichment of ciliary signaling, particularly involving the MKS complex, was evident. SP-MPE exhibited significant dysregulation of mitochondrial metabolism, reflecting a metabolic profile aligned with the Warburg effect. SP-SE tumors showed enhanced activity of immune-related pathways, including interferon signaling and extracellular vesicle dynamics, suggesting a distinct tumor microenvironment.<h4>Conclusion</h4>This pilot study identifies candidate molecular markers in a single-center spinal ependymal tumor cohort.<h4>Clinical trial number</h4>Not applicable."],"pubmed_title":["Multi-omics analysis delineates molecular signatures of spinal ependymal tumor."],"pubmed_authors":["Liu Weihao W, Ning Chao C, Geng Xiaohan X, Wang Bo B, Zhang Yaowu Y, Wang Chong C, Liu Yixiang Y, Zheng Guanghao G, Wang Yongzhi Y, Wang Xinyu X, Li Dong D, Jia Wenqing W"],"additional_accession":[]},"is_claimable":false,"name":"Multi-Omics of Spinal Ependymal Tumor","description":"We conducted a multi-omics analysis of 25 patients, comprising 8 with ependymoma, 10 with myxopapillary ependymoma, and 7 with subependymoma, to identify both shared and distinct genomic, transcriptional, and proteomic features among these subtypes.","dates":{"publication":"Fri Sep 20 00:00:00 BST 2024"},"accession":"PXD056112","cross_references":{"TAXONOMY":["9606"],"pubmed":["41160379"]}}